Feb. 24, 2012 13:00 UTC
REDWOOD CITY, Calif.--(BUSINESS WIRE)--
Natera, formerly known as Gene Security Network, today announced that
the company is scheduled to present at the Citi 2012 Global Health Care
Conference at 4 p.m. EST on Monday, February 27, 2012, at the Waldorf
Astoria in New York City. Matthew Rabinowitz, Ph.D., Natera's chief
executive officer, will provide an overview of the company and an update
on its reproductive genetic testing services.
"Our non-invasive prenatal diagnostic test is moving rapidly through
development, including an NIH-funded clinical investigation, toward
global commercialization later this year," said Rabinowitz. "We look
forward to presenting at this conference and providing background about
how our test will be able to deliver highly accurate results for
detection of multiple conditions, including trisomy 13, 18 and 21, as
well as certain sex chromosome abnormalities."
About Natera
Natera is a genetic testing company that has developed a proprietary
bioinformatics technology (Parental Support) to deliver accurate and
comprehensive high throughput testing for reproductive indications from
tiny quantities of DNA ? as small as that from a single cell. Natera
operates a CLIA laboratory in Redwood City, Calif., providing a host of
reproductive genetic testing services. Test offerings include
preimplantation genetic diagnosis to analyze chromosomal anomalies or
inherited genetic conditions during an IVF cycle in order to select
embryos with the highest probability of becoming healthy children;
products of conception testing following miscarriage to rapidly and
extensively analyze fetal chromosomes in order to understand the cause;
and non-invasive prenatal testing to determine paternity or detect
genetic disease by analyzing fragments of fetal DNA in a pregnant
mother's blood drawn in the first trimester. Non-invasive testing for
paternity is currently available worldwide. Natera's clinical trial for
non-invasive detection of chromosomal anomalies is funded by the NIH and
is being conducted by the leaders in maternal-fetal medicine in the
United States. For more information, visit www.natera.com.
